U.S. Dry Eye Syndrome Treatment Market Size, Share & Trends Analysis Report By Type (Evaporative Dry Eye Syndrome), By Drugs (Restasis, Xiidra), By Product (Cyclosporine), By Dosage Form, By Sales Channel, By Distribution Channel, And Segment Forecasts, 2025 - 2030

Market Size & Trends

The U.S. dry eye syndrome treatment market size was estimated at USD 2.45 billion in 2024 and is projected to grow at a CAGR of 6.0% from 2025 to 2030. Market growth in the country is driven by the high prevalence of dry eye disease (DED), which affected approximately 20 million Americans. As of 2024, this condition demonstrated significant age-related increases in prevalence, particularly among women, with current estimates indicating around 6.8% of the adult population diagnosed. The substantial patient base underscored the urgent need for effective treatment options and indicated a burgeoning market for companies aiming to provide solutions tailored to this demographic’s needs.

The aging U.S. population significantly contributed to the rising incidence of dry eye disease. With older adults being more susceptible, the demographic shift toward a larger population aged 65 and older inherently increased the demand for treatment options. As demographic trends indicated continued growth in this age group, pharmaceutical companies and healthcare providers had to adjust their strategies to meet the evolving needs of this segment, thereby fostering further market expansion. In 2023 and 2024, the market experienced a surge in demand due to the growing awareness of DED, driven by the increased screen time associated with the rise of digital devices. Both younger and older populations spent more time engaging with screens, leading to a higher prevalence of dry eye symptoms.

The market growth was further propelled by advancements in treatment options, which improved diagnosis rates and ultimately increased demand for therapies. By 2024, continuous innovation had resulted in a broader array of effective treatments, including prescription medications and over-the-counter products. As healthcare providers and patients became more educated about dry eye syndrome, the rising diagnosis and treatment-seeking behavior further drove market growth, creating a dynamic environment for industry stakeholders. Moreover, the introduction of new treatment options, such as Miebo, Xiidra, and Tyrvaya, expanded the available therapies for patients, addressing the underlying causes of dry eye and providing relief from symptoms.

The future of the U.S. dry eye syndrome treatment industry looks promising, with several new medications being tested to target specific causes of dry eye. By 2025, treatments such as Reproxalap, IC 265, and Acoltremon are being developed to address dry eye and related conditions, such as allergic conjunctivitis and anterior uveitis. These innovative therapies aim to provide faster and more effective relief from symptoms, with fewer side effects, and are expected to drive market growth in the coming years. As the market continues to evolve, pharmaceutical companies and healthcare providers must remain focused on developing and providing effective treatment options to meet the growing demand.

Type Insights

Evaporative dry eye syndrome dominated the market and accounted for a share of 82.5% in 2024. Meibomian Gland Dysfunction (MGD) affects approximately 21.2% of the U.S. population, making it a significant contributor to evaporative dry eye syndrome and driving demand for effective therapies. Increased awareness and improved diagnosis among healthcare providers and patients further stimulate market growth. Technological advancements, such as lipid-based artificial tears and thermal pulsation systems, enhance treatment outcomes amid rising lifestyle-related incidence.

Aqueous deficient dry eye syndrome is expected to grow lucratively over the forecast period due to reduced tear production from the lacrimal glands. With around 20% of adults over 40 experiencing dry eye symptoms, the aging population significantly drives treatment demand. Moreover, the prevalence of chronic conditions such as diabetes and autoimmune diseases necessitates targeted therapies, supported by increasing awareness and improved diagnosis rates.

Drugs Insights

Xiidra held a substantial market share in 2024. Xiidra (lifitegrast) effectively addresses both the signs and symptoms of dry eye disease by targeting chronic inflammation through its unique mechanism as a lymphocyte function-associated antigen-1 (LFA-1) antagonist. Following its acquisition by Bausch + Lomb, market penetration has improved due to enhanced accessibility. Increased awareness and positive clinical outcomes have further driven prescription rates.

The Cequa segment is projected to grow at the fastest CAGR of 27.0% over the forecast period. Cequa, containing cyclosporine, significantly enhances tear production in dry eye disease patients, with clinical trials indicating improvement rates of 16.6% to 16.8% compared to 8.6% to 9.2% with a placebo. Utilizing innovative NCELL Technology for better ocular absorption, Cequa effectively addresses inflammation associated with chronic dry eye, and growing awareness has increased prescription rates, bolstering its market demand.

Product Insights

Cyclosporine led the market with a revenue share of 54.7% in 2024. Cyclosporine, notably in its ophthalmic emulsion form (e.g., Restasis), has demonstrated clinical efficacy in treating dry eye syndrome, significantly increasing tear production and reducing inflammation. FDA approval solidified its status as a standard treatment, with widespread acceptance and utilization among healthcare providers. Its suitability for long-term management has contributed to increased prescription rates.

Artificial tears are expected to register the fastest CAGR of 10.3% over the forecast period. Artificial tears serve as the first-line treatment for dry eye syndrome, providing immediate relief from symptoms such as dryness and irritation. Their over-the-counter availability, alongside a variety of formulations and a low risk of side effects, enhances patient satisfaction and adherence. Clinical studies show that regular use significantly improves symptoms, driving sustained demand in the U.S. dry eye treatment market.

Dosage Form Insights

Eye drops / solutions led the market and accounted for a share of 35.9% in 2024. Eye drops, especially artificial tears, offer rapid relief from dry eye symptoms by lubricating the eyes and mimicking natural tears. Their over-the-counter availability ensures ease of access, promoting frequent use among patients. A variety of formulations, including preservative-free options and therapeutic ingredients, allows for personalized treatment. Regular application supports ongoing management, making eye drops vital for chronic dry eye care.

Capsules & tablets (for supplements) are expected to register rapid growth over the forecast period. Supplements are effective in alleviating dry eye symptoms by enhancing tear production and reducing inflammation. As patients seek long-term management for this chronic condition, these over-the-counter products provide a convenient option. Growing awareness of nutrition’s role in eye health further boosts demand for these dietary supplements in ocular wellness.

Sales Channel Insights

Prescription drugs dominated the market and accounted for a share of 65.3% in 2024. The efficacy of prescription medications, particularly anti-inflammatory drugs such as cyclosporine and lifitegrast, has proven effective in treating dry eye syndrome by addressing inflammation and enhancing tear production. As of the latest estimates, between 16 million and 49 million Americans were affected by this condition, driving increased demand for effective therapeutic options. Healthcare providers tend to favor prescribing medications that have undergone rigorous clinical testing and regulatory approval for safety and effectiveness. Moreover, prescription therapies often offer advanced treatments not available over-the-counter, catering to patients with moderate to severe dry eye disease who require more intensive management.

OTC drugs are expected to register the fastest CAGR of 6.5% over the forecast period. OTC products have been conveniently available without a prescription, allowing patients to seek immediate relief from dry eye symptoms. These artificial tears often served as the first-line treatment due to their quick and effective symptom relief. Furthermore, the lower cost of OTC options compared to prescription medications makes them appealing, particularly to those without insurance coverage. A variety of formulations, including preservative-free and specialized lubricants, enhances user satisfaction and adherence.

Distribution Channel Insights

Retail pharmacies dominated the market and accounted for a share of 55.4% in 2024. Retail pharmacies offer easy access to a variety of dry eye treatment products, serving as the primary choice for patients seeking immediate relief from symptoms. Many patients turn to retail pharmacies as their first point of contact for healthcare needs, taking advantage of over-the-counter treatments without a prescription. Pharmacists often provide personalized consultations, enhancing customer trust and satisfaction.

Online pharmacies are projected to grow at the fastest CAGR of 6.6% over the forecast period. Online pharmacies have made it easier for patients to access dry eye treatments, offering convenience and accessibility. With a wide range of products available, patients can compare prices and choose the best options for their needs. Competitive pricing and discounts further incentivize online purchasing, made possible by the increasing internet penetration and mobile device usage, particularly in the past decade.

Key U.S. Dry Eye Syndrome Treatment Company Insights

Some key companies operating in the market include Novartis AG; AbbVie Inc.; Sun Pharmaceutical Industries Ltd.; among others. The market remains highly competitive as key players implement strategic initiatives, including new product launches, mergers and acquisitions, and regional expansion, to enhance their global presence while diversifying their product portfolios for broader application coverage. For instance, in January 2023, Bausch & Lomb Corporation, in collaboration with Novaliq GmbH, announced the publication of NOV03 for treating dry eye diseases and related symptoms in the U.S.

• Sun Pharmaceutical Industries Ltd. markets CEQUA (cyclosporine ophthalmic solution) 0.09%, FDA-approved to enhance tear production in dry eye disease patients, leveraging innovative nanomicellar technology for improved bioavailability and stability.

• Janssen Pharmaceutica, a Johnson & Johnson subsidiary, specializes in developing and marketing pharmaceutical products, including ocular health therapies. Although not primarily focused on dry eye treatments, their offerings may support patients experiencing dry eye symptoms related to other ocular conditions.

Recent Developments

• In December 2024, Johnson & Johnson announced a brand update in South Africa, unifying its pharmaceutical and medical technology segments under one name to enhance innovation and drive better healthcare solutions.

• In August 2024, OCuSOFT launched Retaine Allergy prescription-strength antihistamine drops in the U.S., enhancing its product line focused on dry eye solutions and allergy relief.

• In October 2023, Sun Pharmaceutical Industries Limited announced presentation of Phase 4 data in New Orleans, showing sustained improvement in dry eye disease with CEQUA in the U.S.

U.S. Dry Eye Syndrome Treatment Market Report Scope

U.S. Dry Eye Syndrome Treatment Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. dry eye syndrome treatment market report based on type, drugs, product, dosage form, sales channel, distribution channel, and region:

• Product Outlook (Revenue, USD Million, 2018 - 2030)

  • Artificial Tears

  • Cyclosporine

  • Topical Corticosteroids

  • Punctal Plugs

    • Removable

    • Dissolvable

  • Oral Omega Supplements

  • Others

• Drugs Outlook (Revenue, USD Million, 2018 - 2030)

  • Xiidra

  • Restasis

  • Cequa

  • Tyrvaya

  • Eysuvis

  • Others

• Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Evaporative

  • Aqueous Deficient

• Dosage Form Outlook (Revenue, USD Million, 2018 - 2030)

  • Eye Drops / Solutions

  • Ointments and Gels

  • Capsules & Tablets

  • Others

• Sales Channel Outlook (Revenue, USD Million, 2018 - 2030)

  • Prescription

  • OTC

• Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

  • Retail Pharmacies

  • Hospital Pharmacies

  • Online Pharmacies